<i>MET</i>ex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with <i>MET</i>ex14 skipping NSCLC treated with tepotinib.
Paul K. Paik(Memorial Sloan Kettering Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Andreas Johne(Merck KGaA, Darmstadt (Germany)), Wade T. Iams(Vanderbilt University Medical Center), Christopher Stroh(Universität Hamburg), Alexis B. Cortot(Centre National de la Recherche Scientifique), PierFranco Conte(University of Padua), Hiroshi Sakai(Hiroshima University), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Julien Mazières(Université Toulouse III - Paul Sabatier), Rémi Veillon(Centre Hospitalier Universitaire de Bordeaux), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Enriqueta Felip(Institut Català d'Ornitologia), Marina Chiara Garassino(University of Chicago), Michael Thomas, Juergen Scheuenpflug(Merck KGaA, Darmstadt (Germany)), Jo Raskin(Inserm)
Cited by 7
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k